Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas - PubMed (original) (raw)
Comparative Study
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas
J S Lewis et al. J Pathol. 2000 Oct.
Abstract
Angiogenesis is essential to the growth and metastasis of solid tumours. Vascular endothelial growth factor (VEGF) is a potent pro-angiogenic cytokine that is overexpressed in malignant tumours such as invasive carcinoma of the breast. The low oxygen tensions (hypoxia) present in these tumours are known to up-regulate the expression of VEGF by tumour cells. Human macrophages also respond to hypoxia by increasing their release of VEGF in vitro, although the effect of hypoxia on VEGF expression by macrophages in vivo has yet to be demonstrated. The present study compared the expression of VEGF by macrophages in areas of low and high vascularity in 24 invasive breast carcinomas (12 lobular, 12 ductal). The cellular distributions of VEGF protein, CD31 (vessels), and CD68 (macrophages) were compared in sequential sections for each tumour. In ten tumours, both tumour cells and macrophages were immunoreactive for VEGF protein. Use of non-isotopic in situ hybridization to localize VEGF mRNA showed that these cell types also expressed VEGF mRNA. No significant differences in the cellular distribution of VEGF protein were found between lobular and ductal carcinomas. In all tumours, macrophages accumulated in higher numbers in poorly vascularized than in highly vascularized areas. In VEGF-positive tumours, macrophages were immunoreactive for VEGF only in avascular areas where tumour cells also expressed VEGF. This suggests that VEGF expression by these two cell types may be regulated by the same microenvironmental stimuli in breast carcinomas. In addition, significantly more macrophages were present in poorly vascularized areas of VEGF-positive than VEGF-negative tumours. This suggests that VEGF may exert a chemotactic action on macrophages in vivo and guide their migration into avascular tumour sites.
Copyright 2000 John Wiley & Sons, Ltd.
Similar articles
- Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis.
Lee AH, Dublin EA, Bobrow LG, Poulsom R. Lee AH, et al. J Pathol. 1998 Aug;185(4):394-401. doi: 10.1002/(SICI)1096-9896(199808)185:4<394::AID-PATH117>3.0.CO;2-S. J Pathol. 1998. PMID: 9828838 - Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. Brown LF, et al. Clin Cancer Res. 1999 May;5(5):1041-56. Clin Cancer Res. 1999. PMID: 10353737 - The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. Hanrahan V, et al. J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339. J Pathol. 2003. PMID: 12754739 - Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.
Harmey JH, Bouchier-Hayes D. Harmey JH, et al. Bioessays. 2002 Mar;24(3):280-3. doi: 10.1002/bies.10043. Bioessays. 2002. PMID: 11891765 Review. - Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR. Shoji M, et al. Am J Pathol. 1998 Feb;152(2):399-411. Am J Pathol. 1998. PMID: 9466566 Free PMC article. Review.
Cited by
- A Hypoxia-Decidual Macrophage Regulatory Axis in Normal Pregnancy and Spontaneous Miscarriage.
Huang X, Lin Z, Zheng ZM, Shi JL, Lu KY, Wang JR, Li MQ, Shao J. Huang X, et al. Int J Mol Sci. 2024 Sep 8;25(17):9710. doi: 10.3390/ijms25179710. Int J Mol Sci. 2024. PMID: 39273657 Free PMC article. Review. - The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.
Lorestani P, Dashti M, Nejati N, Habibi MA, Askari M, Robat-Jazi B, Ahmadpour S, Tavakolpour S. Lorestani P, et al. Discov Oncol. 2024 Aug 26;15(1):369. doi: 10.1007/s12672-024-01256-x. Discov Oncol. 2024. PMID: 39186144 Free PMC article. Review. - Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8T cells and IFNγ.
Tokumasu M, Nishida M, Zhao W, Chao R, Imano N, Yamashita N, Hida K, Naito H, Udono H. Tokumasu M, et al. Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2404778121. doi: 10.1073/pnas.2404778121. Epub 2024 Jul 17. Proc Natl Acad Sci U S A. 2024. PMID: 39018197 - Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.
Zhao Y, Chen C, Chen K, Sun Y, He N, Zhang X, Xu J, Shen A, Zhao S. Zhao Y, et al. Sci Rep. 2024 May 28;14(1):12163. doi: 10.1038/s41598-024-62668-x. Sci Rep. 2024. PMID: 38806553 Free PMC article. - Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C, Liu C, Liu W, Zhou R, Zhao L. Qian C, et al. Front Immunol. 2023 Dec 15;14:1291530. doi: 10.3389/fimmu.2023.1291530. eCollection 2023. Front Immunol. 2023. PMID: 38193080 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical